到 2030 年基因编辑市场预测：按产品、技术、应用、最终用户和地区进行的全球分析

根据 Stratistics MRC 的数据，2023 年全球基因编辑市场规模为 74.5 亿美元，预计预测期内年复合成长率为 17.5%，到 2030 年将达到 230.5 亿美元。

一组被称为「基因编辑」的技术允许研究人员修改生物体的 DNA。这些技术使得改变、添加或去除基因组内特定位置的遗传物质成为可能。基因组编辑对于人类疾病预防和治疗来说是一个有吸引力的领域。更复杂的疾病，如癌症、心臟病、精神疾病和爱滋病毒感染疾病，也可以使用这项技术来治疗或预防。

根据美国国立卫生研究院 (NIH) 的数据，大约有 7,000 种罕见疾病影响着 2500 至 3000 万美国人。

基因组学的应用日益广泛

基因组学越来越多地用于测试食品品质和安全。基因组编辑技术对于发现新药物以及识别和治疗人类遗传疾病至关重要。 NGS、DNA 分析和分析以及动植物基因工程都采用基因组编辑。在评估鱼类族群时，NGS 可用于 DNA 条码来识别鱼卵和幼虫，或全面表征鱼类群落。因此，在预测期内，随着基因组分析应用领域的扩大，对基因组编辑技术的需求可能会增加。

高成本

基因编辑疗法的研究和开发成本高且耗时。公司和组织可能很难筹集彻底的初步测试和临床试验所需的资金。基因编辑药物的开发很大程度上依赖临床试验，而临床试验的费用相当昂贵。这些试验通常涉及多个阶段和大量人员，需要证明基因编辑疗法的安全性和有效性。因此，高成本是市场拓展的主要障碍。

遗传病患病率上升

推动基因编辑市场的主要因素之一是遗传疾病盛行率的上升。这一趋势的本质特征是被诊断出患有罕见疾病和各种遗传性疾病的人数增加。 CRISPR-Cas9等基因编辑技术能够识别和纠正导致这些疾病的潜在遗传异常，因此患者终于可以看到希望。这些因素正在推动市场需求。

CRISPR 的脱靶效应

基因编辑技术的一个显着限制是CRISPR技术的脱靶效应。儘管 CRISPR-Cas9 可以以令人难以置信的精确度靶向特定基因，但它也可能导致预期目标以外的位置发生意外修改。由于这种脱靶活性，CRISPR技术的应用可能会带来风险和困难。这些因素都阻碍了市场的扩张。

COVID-19 的影响

这场大流行使基因编辑产业受益，因为社交距离规范和医院床位短缺迫使家庭患者照护系统充分适应。 COVID-19大流行彻底改变了我们的生活。它也进一步加速了科学界对创造力和协作的承诺。随着疫情在世界各地蔓延，科学家正忙于开发治疗方法、疫苗接种和诊断方法。科学家们正在转向高通量实验室自动化、人工智慧和机器学习来应对导致 COVID-19 的新型冠状病毒 SARS-CoV-2。 SARS-CoV-2 对于隔离感染患者并观察适当的医疗反应是必要的。因此，基因编辑市场受益于 COVID-19 的爆发。

试剂和消耗品部分预计将在预测期内成为最大的部分

试剂和消耗品部分估计占最大份额。试剂和消耗品包括各种物品，例如箔片密封件、玻片支架、板、晶片、管条、文库製备、精製和目标富集套件。由于基因组学在各行业的应用不断增长，预计消耗品市场将会成长。文库製备技术的进步也使得 NGS 在磊晶和转录组学中的应用成为可能。这些试剂盒用于定序应用，例如标靶定序和全基因组定序。

簇状规则间隔的短回文重复片段预计在预测期内具有最高的年复合成长率

预计聚集的等距短回文重复片段将在预测期内实现良好的成长。作为传统基因修饰方法的替代方法，CRISPR 成簇的规则间隔截断回文重复序列已成为基因编辑的重要工具。 Cas9 酶是 CRISPR 与传统 DNA 编辑的不同之处。 CRISPR 透过去除受损或不必要的 DNA 序列来重新排列基因，使剩余的 DNA 呈现新的配置。

占比最高的地区

在估计期间，北美占据了最大的市场占有率。基因编辑最重要的区域市场是北美。美国是该地区的主要收益来源。在美国，创业投资、政府机构和私人公司正在基因编辑领域进行大量资金和投资。这笔资金筹措加速了基因编辑技术的研究、开发和商业化。治疗性介入的发展和基因编辑操作的扩展是由于资金筹措的提供而成为可能的。

复合年复合成长率最高的地区：

预计亚太地区在预测期内将出现盈利成长。这是由于技术突破的增加、新兴地区生物技术产业的崛起以及癌症和其他遗传异常盛行率的上升而推动的。 CRISPR技术创新在日本仍在显着成长。同时，新兴的 CRISPR 研究预计将推动印度市场的成长。此外，印度研究人员也开发了广泛使用的 CRISPR-Cas9 基因编辑方法的不同变异。这种变异可以提高基因编辑的精确度，而不会导致意外的 DNA 变化。因此，这些变数预计将影响未来年度的亚太基因编辑市场。

提供免费客製化

本报告的所有客户都将收到以下免费自订选项之一：

• 公司简介
  • 其他市场参与企业的综合分析（最多 3 家公司）
  • 主要企业SWOT分析（最多3家企业）
• 区域分割
  • 根据客户兴趣对主要国家的市场估计/预测/年复合成长率（註：基于可行性检查）
• 竞争基准化分析
  • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

• 概述
• 利害关係人
• 调查范围
• 调查方法
  • 资料探勘
  • 资料分析
  • 资料检验
  • 研究途径
• 调查来源
  • 主要调查来源
  • 二次调查来源
  • 先决条件

第3章市场趋势分析

介绍

促进因素

抑制因素

机会

威胁

产品分析

技术分析

应用分析

最终用户分析

新兴市场

新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

• 供应商的议价能力
• 买方议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第5章全球基因编辑市场：副产品

• 介绍
• 软体及系统
• 服务
• 试剂/消耗品

第6章全球基因编辑市场：依技术分类

• 介绍
• 转录激活剂样效应核酸酶
• 反义
• 成簇规则间隔短回文重复序列 (CRISPR)
• 锌指核酸酶 (ZFN)
• 其他技术

第7章全球基因编辑市场：依应用分类

• 介绍
• 基因工程
• 细胞株工程
• 药物研发发现与开发
• 其他用途

第8章全球基因编辑市场：依最终用户分类

• 介绍
• 学术研究所
• 製药和生物技术公司
• 其他最终用户

第9章全球基因编辑市场：按地区

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 纽西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 卡达
  • 南非
  • 中东和非洲其他地区

第10章进展

• 合约、伙伴关係、协作和合资企业
• 收购和合併
• 新产品发布
• 业务扩展
• 其他关键策略

第11章公司简介

• Sangamo Therapeutics, Inc.
• Beam Therapeutics
• Integrated DNA Technologies, Inc.
• Thermo Fisher Scientific
• Horizon Discovery Ltd.
• Precision Biosciences
• CRISPR Therapeutics
• GeneScript
• Agilent Technologies
• Intellia Therapeutics, Inc.
• Caribou Biosciences, Inc.
• Lonza
• Perkinelmer
• Editas Medicine
• Tecan Life Sciences
• Amsbio
• Creative Biogene

According to Stratistics MRC, the Global Gene Editing Market is accounted for $7.45 billion in 2023 and is expected to reach $23.05 billion by 2030 growing at a CAGR of 17.5% during the forecast period. A group of technologies known as "gene editing" enables researchers to modify an organism's DNA. These technologies make it possible to change, add, or remove genetic material at particular locations within the genome. Genome editing is a fascinating field for both illness prevention and treatment in humans. More complicated conditions like cancer, heart disease, mental illness, and HIV infection may also be treated and prevented by using it.

According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans.

Market Dynamics:

Driver:

Rising applications of genomics

Genomics is increasingly being used in food quality and safety testing. Technologies for editing genomes are essential for both finding new drugs and identifying and treating genetic diseases in humans. NGS, DNA analysis and profiling, and genetic engineering of plants and animals all employ genome editing. When evaluating fish populations, NGS can be utilized for DNA barcoding to identify fish eggs and larvae as well as to fully characterize fish communities. Therefore, during the projection period, there will likely be a rise in demand for genome editing technologies due to the expanding application areas of genomics.

Restraint:

High cost

Gene editing therapy research and development can be costly and time-consuming. It could be difficult for businesses and organizations to get the financing needed for in-depth pre- and clinical testing. The development of gene editing medicine heavily relies on clinical studies, which are quite expensive. These trials, which usually involve several phases and a large number of people, are required to show the safety and effectiveness of gene editing therapy. Therefore, high costs are a significant barrier to market expansion.

Opportunity:

Rising prevalence of genetic illnesses

One major factor fueling the gene editing market is the increase in the prevalence of genetic illnesses. An increase in the number of people receiving diagnoses for uncommon diseases and different genetic disorders essentially characterizes this trend. Patients may finally have hope due to gene editing technologies like CRISPR-Cas9, which have the ability to identify and fix the underlying genetic abnormalities causing these illnesses. These factors propel market demand.

Threat:

Off-target impacts of CRISPR

A significant constraint of gene editing technology is the off-target impacts of CRISPR technology. Although CRISPR-Cas9 can target certain genes with astonishing precision, it can also cause unintentional alterations at places other than the intended target. The application of CRISPR technology may present risks and difficulties as a result of this off-target activity. These factors hinder market expansion.

COVID-19 Impact

The industry for gene editing benefited from the pandemic because social distancing norms and a shortage of hospital beds forced home-based patient care systems to adapt to the fullest. The COVID-19 pandemic has changed our lives. It has also intensified the already swift inclinations toward creation and cooperation among the scientific community. With the pandemic spreading across the globe, scientists are working feverishly to develop treatments, vaccinations, and diagnoses. To tackle SARS-CoV-2, the new coronavirus that causes COVID-19, scientists are looking into high-throughput experimental automation, artificial intelligence, and machine learning. The SARS-CoV-2 is necessary for isolating infected patients and observing appropriate medical responses. Thus, the market for gene editing benefited from the COVID-19 epidemic.

The reagents & consumables segment is expected to be the largest during the forecast period

The reagents & consumables segment is estimated to hold the largest share. Reagents and consumables encompass a wide range of items, including foil seals, slide holders, plates, chips, tube strips, library preparation, purification, and target enrichment kits. The market for consumables is predicted to rise as a result of genomics' expanding applicability in a variety of industries. Utilizing NGS in epigenetic and transcriptomics has also been made possible by developments in library preparation technology. Applications for sequencing, including targeted and whole-genome sequencing, employ these kits.

The clustered regularly interspaced short palindromic repeats segment is expected to have the highest CAGR during the forecast period

The clustered regularly interspaced short palindromic repeats segment is anticipated to have lucrative growth during the forecast period. As an alternative to conventional genetic alteration methods, CRISPR-Clustered Regularly Interspaced Short Palindromic Repeats have become an essential tool for gene editing. The Cas9 enzymes set CRISPR apart from previous types of DNA editing. By removing damaged or undesirable DNA sequences, CRISPR reorganizes genes so that the remaining DNA can take on new configurations.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The most significant regional market for gene editing is North America. The US has become this region's main source of revenue. In the US, venture capitalists, governmental organizations, and private companies have made large financial and investment contributions in the gene editing field. Research and development, as well as the commercialization of gene editing technologies, have been accelerated by this financing. The development of therapeutic interventions and the expansion of gene editing businesses have been made possible by the availability of funding.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. This is due to increasing technological breakthroughs, a thriving biotechnology industry in emerging regions, and the rising prevalence of cancer and other genetic abnormalities. Innovation in CRISPR technology is still growing significantly in Japan. On the other hand, new CRISPR research is anticipated to propel market growth in India. Additionally, researchers in the nation developed a distinct variation of the widely used CRISPR-Cas9 gene-editing method. The variant may increase the accuracy of gene editing without causing unintended DNA changes. Therefore, in the upcoming years, it is anticipated that these variables will have an effect on the Asia-Pacific gene editing market.

Key players in the market

Some of the key players in the Gene Editing Market include: Sangamo Therapeutics, Inc., Beam Therapeutics, Integrated DNA Technologies, Inc., Thermo Fisher Scientific, Horizon Discovery Ltd., Precision Biosciences, CRISPR Therapeutics, GeneScript, Agilent Technologies, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Lonza, Perkinelmer, Editas, edicine, Tecan Life Sciences, Amsbio and Creative Biogene.

Key Developments:

In November 2022, Thermo Fisher Scientific (US) announced the launch of Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution suitable for commercial and clinical applications associated with AAV-based gene therapies.

In June 2022, Lonza (Switzerland) and Adva entered into a license agreement that will allow Adva to develop innovative solutions for the cell and gene therapies industry.

In February 2023, Gen Script (China) announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company's advanced gene-synthesis capability and enables Gen Script to provide the service levels required for novel vaccine and therapeutic development in life sciences.

Products Covered:

• Software & Systems
• Services
• Reagents & Consumables

Technologies Covered:

• Transcription Activator-Like Effector Nuclease
• Antisense
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
• Zinc Finger Nuclease (ZFN)
• Other Technologies

Applications Covered:

• Genetic Engineering
• Cell Line Engineering
• Drug Discovery & Development
• Other Applications

End Users Covered:

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Product Analysis

3.7 Technology Analysis

3.8 Application Analysis

3.9 End User Analysis

3.10 Emerging Markets

3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gene Editing Market, By Product

• 5.1 Introduction
• 5.2 Software & Systems
• 5.3 Services
• 5.4 Reagents & Consumables

6 Global Gene Editing Market, By Technology

• 6.1 Introduction
• 6.2 Transcription Activator-Like Effector Nuclease
• 6.3 Antisense
• 6.4 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
• 6.5 Zinc Finger Nuclease (ZFN)
• 6.6 Other Technologies

7 Global Gene Editing Market, By Application

• 7.1 Introduction
• 7.2 Genetic Engineering
• 7.3 Cell Line Engineering
• 7.4 Drug Discovery & Development
• 7.5 Other Applications

8 Global Gene Editing Market, By End User

• 8.1 Introduction
• 8.2 Academic and Research Institutes
• 8.3 Pharmaceutical and Biotechnology Companies
• 8.4 Other End Users

9 Global Gene Editing Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Sangamo Therapeutics, Inc.
• 11.2 Beam Therapeutics
• 11.3 Integrated DNA Technologies, Inc.
• 11.4 Thermo Fisher Scientific
• 11.5 Horizon Discovery Ltd.
• 11.6 Precision Biosciences
• 11.7 CRISPR Therapeutics
• 11.8 GeneScript
• 11.9 Agilent Technologies
• 11.10 Intellia Therapeutics, Inc.
• 11.11 Caribou Biosciences, Inc.
• 11.12 Lonza
• 11.13 Perkinelmer
• 11.14 Editas Medicine
• 11.15 Tecan Life Sciences
• 11.16 Amsbio
• 11.17 Creative Biogene

List of Tables

• Table 1 Global Gene Editing Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Gene Editing Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
• Table 4 Global Gene Editing Market Outlook, By Services (2021-2030) ($MN)
• Table 5 Global Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
• Table 6 Global Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
• Table 7 Global Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
• Table 8 Global Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
• Table 9 Global Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
• Table 10 Global Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
• Table 11 Global Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 12 Global Gene Editing Market Outlook, By Application (2021-2030) ($MN)
• Table 13 Global Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
• Table 14 Global Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
• Table 15 Global Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
• Table 16 Global Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 17 Global Gene Editing Market Outlook, By End User (2021-2030) ($MN)
• Table 18 Global Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
• Table 19 Global Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 20 Global Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 21 North America Gene Editing Market Outlook, By Country (2021-2030) ($MN)
• Table 22 North America Gene Editing Market Outlook, By Product (2021-2030) ($MN)
• Table 23 North America Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
• Table 24 North America Gene Editing Market Outlook, By Services (2021-2030) ($MN)
• Table 25 North America Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
• Table 26 North America Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
• Table 27 North America Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
• Table 28 North America Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
• Table 29 North America Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
• Table 30 North America Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
• Table 31 North America Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 32 North America Gene Editing Market Outlook, By Application (2021-2030) ($MN)
• Table 33 North America Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
• Table 34 North America Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
• Table 35 North America Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
• Table 36 North America Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 37 North America Gene Editing Market Outlook, By End User (2021-2030) ($MN)
• Table 38 North America Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
• Table 39 North America Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 40 North America Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 41 Europe Gene Editing Market Outlook, By Country (2021-2030) ($MN)
• Table 42 Europe Gene Editing Market Outlook, By Product (2021-2030) ($MN)
• Table 43 Europe Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
• Table 44 Europe Gene Editing Market Outlook, By Services (2021-2030) ($MN)
• Table 45 Europe Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
• Table 46 Europe Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
• Table 47 Europe Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
• Table 48 Europe Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
• Table 49 Europe Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
• Table 50 Europe Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
• Table 51 Europe Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 52 Europe Gene Editing Market Outlook, By Application (2021-2030) ($MN)
• Table 53 Europe Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
• Table 54 Europe Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
• Table 55 Europe Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
• Table 56 Europe Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 57 Europe Gene Editing Market Outlook, By End User (2021-2030) ($MN)
• Table 58 Europe Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
• Table 59 Europe Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 60 Europe Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 61 Asia Pacific Gene Editing Market Outlook, By Country (2021-2030) ($MN)
• Table 62 Asia Pacific Gene Editing Market Outlook, By Product (2021-2030) ($MN)
• Table 63 Asia Pacific Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
• Table 64 Asia Pacific Gene Editing Market Outlook, By Services (2021-2030) ($MN)
• Table 65 Asia Pacific Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
• Table 66 Asia Pacific Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
• Table 67 Asia Pacific Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
• Table 68 Asia Pacific Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
• Table 69 Asia Pacific Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
• Table 70 Asia Pacific Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
• Table 71 Asia Pacific Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 72 Asia Pacific Gene Editing Market Outlook, By Application (2021-2030) ($MN)
• Table 73 Asia Pacific Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
• Table 74 Asia Pacific Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
• Table 75 Asia Pacific Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
• Table 76 Asia Pacific Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 77 Asia Pacific Gene Editing Market Outlook, By End User (2021-2030) ($MN)
• Table 78 Asia Pacific Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
• Table 79 Asia Pacific Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 80 Asia Pacific Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 81 South America Gene Editing Market Outlook, By Country (2021-2030) ($MN)
• Table 82 South America Gene Editing Market Outlook, By Product (2021-2030) ($MN)
• Table 83 South America Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
• Table 84 South America Gene Editing Market Outlook, By Services (2021-2030) ($MN)
• Table 85 South America Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
• Table 86 South America Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
• Table 87 South America Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
• Table 88 South America Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
• Table 89 South America Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
• Table 90 South America Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
• Table 91 South America Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 92 South America Gene Editing Market Outlook, By Application (2021-2030) ($MN)
• Table 93 South America Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
• Table 94 South America Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
• Table 95 South America Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
• Table 96 South America Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 97 South America Gene Editing Market Outlook, By End User (2021-2030) ($MN)
• Table 98 South America Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
• Table 99 South America Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 100 South America Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 101 Middle East & Africa Gene Editing Market Outlook, By Country (2021-2030) ($MN)
• Table 102 Middle East & Africa Gene Editing Market Outlook, By Product (2021-2030) ($MN)
• Table 103 Middle East & Africa Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
• Table 104 Middle East & Africa Gene Editing Market Outlook, By Services (2021-2030) ($MN)
• Table 105 Middle East & Africa Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
• Table 106 Middle East & Africa Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
• Table 107 Middle East & Africa Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
• Table 108 Middle East & Africa Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
• Table 109 Middle East & Africa Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
• Table 110 Middle East & Africa Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
• Table 111 Middle East & Africa Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 112 Middle East & Africa Gene Editing Market Outlook, By Application (2021-2030) ($MN)
• Table 113 Middle East & Africa Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
• Table 114 Middle East & Africa Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
• Table 115 Middle East & Africa Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
• Table 116 Middle East & Africa Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 117 Middle East & Africa Gene Editing Market Outlook, By End User (2021-2030) ($MN)
• Table 118 Middle East & Africa Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
• Table 119 Middle East & Africa Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 120 Middle East & Africa Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)